Vepdegestrant (ARV-471) yielded a statistically significant and clinically meaningful improvement in progression-free ...

Pfizer's stock is poised for growth due to its strong pipeline, smart cost management, and recovery from COVID-19 revenue ...

The Breast Cancer market is undergoing significant expansion, driven by increasing disease prevalence and the introduction of innovative therapeutic options from companies such as ...

Funding will support Moores Cancer Center’s efforts to develop a unique, large-scale program to drive early detection and ...

Early toxicities associated with a 3-week hypofractionated radiotherapy regimen do not raise initial safety concerns in women ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

“We are grateful to Pfizer for their visionary support ... Researchers at Moores are targeting colorectal, breast, cervical and prostate cancer as the primary focus of the early detection ...